4D Molecular Therapeutics, Inc. Stock

Equities

FDMT

US35104E1001

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:02 2024-05-16 pm EDT 5-day change 1st Jan Change
25.67 USD +0.35% Intraday chart for 4D Molecular Therapeutics, Inc. +0.12% +26.70%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 3.63M Sales 2025 * 6.18M Capitalization 1.33B
Net income 2024 * -158M Net income 2025 * -191M EV / Sales 2024 * 227 x
Net cash position 2024 * 502M Net cash position 2025 * 403M EV / Sales 2025 * 149 x
P/E ratio 2024 *
-8.46 x
P/E ratio 2025 *
-8.69 x
Employees 171
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.5%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : 4D Molecular Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target MT
RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier MT
Certain Restricted Stock Units of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain Stock Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain Warrants of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing MT
BMO Capital Cuts 4D Molecular Therapeutics' Price Target to $63 From $70, Keeps Outperform Rating MT
Jefferies Raises 4D Molecular Therapeutics' Price Target to $58 From $30, Maintains Buy Rating MT
4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis MT
4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis CI
Transcript : 4D Molecular Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:30 AM
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
More news
1 day+0.35%
1 week+0.12%
Current month+7.27%
1 month-4.04%
3 months-5.83%
6 months+132.73%
Current year+26.70%
More quotes
1 week
24.77
Extreme 24.77
27.36
1 month
22.75
Extreme 22.75
27.84
Current year
16.64
Extreme 16.64
36.25
1 year
9.44
Extreme 9.44
36.25
3 years
5.32
Extreme 5.32
36.25
5 years
5.32
Extreme 5.32
55.11
10 years
5.32
Extreme 5.32
55.11
More quotes
Managers TitleAgeSince
Founder 49 13-09-11
Founder 62 13-09-11
Director of Finance/CFO 51 23-09-11
Members of the board TitleAgeSince
Chairman 63 20-07-31
Director/Board Member 63 20-06-30
Director/Board Member 60 15-12-31
More insiders
Date Price Change Volume
24-05-16 25.64 +0.23% 526,900
24-05-15 25.58 -0.66% 429,968
24-05-14 25.75 +0.70% 425,599
24-05-13 25.57 -0.51% 593,875
24-05-10 25.7 +0.23% 397,446

Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT

More quotes
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
25.64 USD
Average target price
52.3 USD
Spread / Average Target
+103.98%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW